Uroplasty, Inc. recently announced an expansion of coverage of percutaneous nerve stimulation (PTNS) using its Urgent PC neuromodulation system for the treatment of symptoms of overactive bladder syndrome.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.